glp 1 drug made by eli lilly Why is suddenly pulling ahead in the GLP-1 weight-loss race glp 1 zepbound Eli Lilly's

Orally deliverable nanoformulation of liraglutide against type 2 diabetic rat model

J Endocrinol 2023, 258(2)

Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8

Microdosing may not produce the same level of weight loss seen with standard dosing, and outcomes depend on individual factors and medical oversight

121 National Center for Biotechnology Information (2023e)